Meningococcal Vaccine Market Growth by 2026| Bio-Manguinhos, Bio-Med, Chongqing Zhifei Biological Products, GlaxoSmithKline, Hualan Biological Engineering, Incepta Pharmaceuticals, Pfizer, Sanofi S.A., Serum Institute, Walvax Biotechnology

The global meningococcal vaccine market was valued at $1,935.5 million in 2018, and is projected to reach $4,192.5 million by 2026, registering a CAGR of 9.5% from 2019 to 2026. Invasive meningococcal disease (IMD) is a bacterial infection caused by a gram-negative coccus, Neisseria meningitidis, which includes spectrum of infections including meningitis, bacteremia (meningococcemia), and bacteremia pneumonia.

Check for the sample here - https://bit.ly/38WZHip

Although meningococcal disease is rare but is associated with high fatality of up to 50% if left untreated and often results in serious complications thereafter. Meningococcal meningitis results in infection of the lining of the brain and spinal cord and also has a potential to cause large epidemics as well as endemics. The disease is generally transmitted through direct contact with droplets of respiratory or throat secretions from patients or asymptomatic carriers.

Various serotypes of N. meningitidis are included in 12 serogroups of which only 5 serogroups including A, B, C, W, and Y are responsible for the majority of disease worldwide. However, circulation of these serogroups is highly unpredictable and varies over time across age groups and geographies. Vaccines for each of these serogroups are available in the market.

The List of companies covered in this Reports are:
Bio-Manguinhos
Bio-Med Pvt. Limited
Chongqing Zhifei Biological Products Co.
Ltd.
GlaxoSmithKline Plc
Hualan Biological Engineering Inc.
Incepta Pharmaceuticals Ltd.
Pfizer Inc.
Sanofi S.A.
Serum Institute of India Pvt. Ltd
and Walvax Biotechnology Co.
Ltd.

Inquire for Discount - https://bit.ly/3euINch

The global meningococcal vaccine market is segmented on the basis of serogroup, vaccine type, end user, and region. The serogroups covered in the study include MenACWY, MenB/BC, MenC, MenAC, and MenA. Depending on vaccine type, the market is classified into conjugate, polysaccharide, and subcapsular. According to end user, the market is segmented into pediatric, adults, and travelers. By region, the market is studied across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, the Netherlands, Spain, and rest of Europe), Asia-Pacific (China, Australia, and rest of Asia-Pacific), and LAMEA (Latin America, the Middle East, and Africa).

For Purchase this report: https://www.premiummarketinsights.com/buy/AMR00028859

Contact Info:
Name: Sameer Joshi
Email: sales@premiummarketinsights.com
Organization: Premium Market Insights
Phone: +1-646-491-9876

About Premium Market Insights:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider.

This release was published on openPR.